Cowen’s healthcare analyst Phil Nadeau is weighing in with a few insights on Achillion Pharmaceuticals (NASDAQ:ACHN), following new trial results which demonstrated that a combination of the company’s ACH-3102 and Gilead’s Sovaldi triggered a 6-week cure in treatment-naïve genotype 1 HCV-infected patients. The analyst rates the stock Outperform, without suggesting a price target.
Nadeau noted, “The updated data from the trial continue to be impressive, and ACH-3102 appears to be the best in class NS5A. GILD has tested 6 week regimens in the past, and those regimens have achieved 95% SVR. However, both contained a third DAA in addition to Harvoni. While the number of patients in the Achillion trial is small, the patients do not seem to be particularly easy to treat. Therefore, while the experience is limited, ACH-3102 + Sovaldi has generated the best data thus far for a two drug regimen. This suggests that ACH-3102 is perhaps the most potent NS5A inhibitor in development or on the market.”
The analyst added, “It is also fair to say that Sovaldi is the major workhorse of the Sovaldi + ACH-3102 regimen. In order to build a wholly-owned commercially competitive regimen, Achillion will need a safe and effective nuc.”
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally.